Sino acquires Gmax's obesity drug candidate. Simcere partners with Mass General Brigham on select research projects.

The Biden Administration’s latest Executive Order is aimed at shoring up investment in the US and securing supply chains for pharma and biotech products and is already impacting China's CDMO sector, but the long-term impact may be more nuanced, experts predict.

Emerging Company Profile: Founded by former executives of China’s national innovation darling Betta Pharma, Beijing-based Jacobio is focused on novel oncology assets, led by a KRAS inhibitor that's set to begin Phase I and IIa studies in the US and China for solid tumors.

Life science and pharma companies have been actively investing in Asia over the past month as they look to increase regional manufacturing capacities to tap into burgeoning markets and meet rising demand for new technologies, biologics and high-quality products, while Chinese firms have also been expanding their international presence.